Summary
Unable to accurately assess alignment because the AI-generated response text containing the claims to evaluate was not provided—only a list of claims. Several claims contain multiple specific factual/time-range assertions (e.g., '4-6 weeks before' and '3 weeks after last dose') and quantitative titers ('20-50% lower antibody titers') that cannot be verified against the supplied label excerpts beyond the single statement that live vaccines should be avoided and that COSENTYX may alter immune response to live vaccines.
Category Scores
Accurate Statements
Secukinumab targets IL-17A and inhibits interaction with the IL-17 receptor.
Label Section 12.1: 'Secukinumab selectively binds IL-17A and inhibits interaction with IL-17 receptor.'
Avoid use of live vaccines in patients treated with COSENTYX.
Label Section 5.7: 'Avoid use of live vaccines in patients treated with COSENTYX.'
COSENTYX may alter immune response to live vaccines.
Label Section 5.7: 'COSENTYX may alter immune response to live vaccines.'
Unsupported Statements
Live vaccines should not be given concurrently with COSENTYX (secukinumab).
Supplied excerpts only state to avoid use of live vaccines in patients treated with COSENTYX; they do not specify 'concurrently.'
Live attenuated vaccines (e.g., MMR, varicella, oral polio) are contraindicated during secukinumab treatment.
Label excerpt states 'Avoid use of live vaccines' but does not use the term 'contraindicated' nor list example vaccines.
Use of live vaccines during secukinumab treatment increases the risk from live attenuated vaccines.
Label excerpt says COSENTYX may alter immune response to live vaccines, but provided text does not state an increased risk from live attenuated vaccines.
Patients should avoid live vaccines during treatment and for several weeks after stopping secukinumab.
No post-discontinuation waiting period is provided in the supplied excerpts.
Avoid live vaccines for at least 4-6 weeks before starting secukinumab.
No pre-initiation waiting period is provided in the supplied excerpts.
Avoid live vaccines until 3 weeks after the last dose of secukinumab.
No specific '3 weeks' interval is provided in the supplied excerpts.
Non-live (inactivated or recombinant) vaccines are generally safe with secukinumab.
Supplied excerpts do not address safety of non-live vaccines.
Inactivated or recombinant vaccines (e.g., flu shot, COVID-19 vaccines, Tdap) are generally safe with secukinumab.
Supplied excerpts do not address safety of specific non-live vaccines.
Guidelines advise completing vaccinations before starting secukinumab if possible, especially live ones.
Label excerpt states to complete all age-appropriate vaccinations prior to initiating treatment, but does not explicitly mention 'guidelines' or 'especially live ones.'
Antibody responses to vaccines may be reduced due to secukinumab immunosuppression.
Label excerpt only states COSENTYX may alter immune response to live vaccines; it does not state reduced antibody responses or 'immunosuppression' in general.
Non-live vaccines can be given anytime during secukinumab treatment.
No timing guidance for non-live vaccines is provided in the supplied excerpts.
Some studies show 20-50% lower antibody titers after treatment with secukinumab.
No quantitative titers are provided in the supplied excerpts.
Flu vaccination with an inactivated vaccine is safe with secukinumab.
Supplied excerpts do not address influenza vaccine (inactivated) safety.
Response to annual inactivated flu shots may be weaker in patients on secukinumab.
Supplied excerpts do not address reduced response to inactivated influenza vaccines.
COVID-19 vaccines that are mRNA or protein-based are safe with secukinumab.
Supplied excerpts do not address COVID-19 vaccine safety or platform types.
Full series and boosters of COVID-19 vaccines are advised for patients on secukinumab.
Supplied excerpts only state to complete all age-appropriate vaccinations per immunization guidelines prior to initiating COSENTYX; they do not advise COVID-19 series/boosters specifically.
Shingrix (recombinant shingles vaccine) is safe with secukinumab.
Supplied excerpts do not address recombinant shingles vaccine safety.
Shingrix is preferred over live Zostavax in patients receiving secukinumab.
Supplied excerpts do not discuss vaccine preference between specific products.
Pneumococcal vaccines (PCV13/20, PPSV23) are safe with secukinumab.
Supplied excerpts do not address pneumococcal vaccine safety.
Routine pneumococcal vaccination is recommended for at-risk patients receiving secukinumab.
Supplied excerpts do not include pneumococcal vaccine recommendations or 'at-risk' language.
Live vaccines (e.g., yellow fever, nasal flu) are not safe with secukinumab.
Label excerpt does not list specific live vaccines or use 'not safe'; it only says avoid live vaccines in treated patients.
Live vaccines should be deferred until off secukinumab.
Label excerpt says avoid live vaccines in patients treated with COSENTYX; it does not specify 'defer until off' in those terms or provide timing.
Pediatric labeling mirrors adults: no live vaccines during secukinumab treatment.
Supplied excerpts do not address whether pediatric labeling mirrors adults for live vaccines.
Pregnancy registries note no specific vaccine bans with secukinumab.
No pregnancy registry or vaccine-ban statement is provided in the supplied excerpts.
In pregnancy, inactivated vaccines are preferred over live vaccines with secukinumab.
Supplied excerpts do not provide pregnancy-specific immunization preferences.
Secukinumab blocks IL-17 and impairs immune control of viral replication in live vaccines.
Label excerpt supports IL-17A binding and altered immune response to live vaccines, but does not state 'immune control of viral replication in live vaccines.'
Impaired immune control of viral replication in live vaccines increases the risk of disseminated infections like varicella.
No such specific causal risk statement or varicella example is provided in the supplied excerpts.
Contradictions
Low
AI Statement
Avoid live vaccines until 3 weeks after the last dose of secukinumab.
Label Reference
Section 5.7 and Section 2.1 provided excerpts: no specific '3 weeks after last dose' interval is stated.
Low
AI Statement
Avoid live vaccines for at least 4-6 weeks before starting secukinumab.
Label Reference
Section 5.7 and Section 2.1 provided excerpts: no specific '4-6 weeks before' interval is stated.
Important Omissions
The AI claims about live vaccines do not consistently reference the label language that emphasizes 'avoid use of live vaccines' and 'complete all age-appropriate vaccinations prior to initiating COSENTYX' (Section 2.1 and 5.7).
Importance:
Moderate
The AI claims include many specific vaccine examples (MMR, varicella, oral polio, yellow fever, nasal flu; flu, COVID-19, Tdap; Shingrix, Zostavax; PCV13/20, PPSV23) and platform/product-specific assertions without support in the provided excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Over-specific timing intervals (e.g., '4-6 weeks before' and '3 weeks after last dose') and product/platform safety assertions for vaccines are not supported by the supplied label excerpts. This could lead to incorrect vaccination scheduling or assumptions about safety.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Many claims add specific vaccine examples, safety statements for non-live vaccines, and precise pre/post discontinuation intervals that are not present in the supplied prescribing-information excerpts.
Suggested Improvement
Limit statements about immunizations to the provided label language: (1) complete all age-appropriate vaccinations prior to initiating COSENTYX, and (2) avoid use of live vaccines in patients treated with COSENTYX and that COSENTYX may alter immune response to live vaccines. Remove or qualify unsupported specifics (timing intervals and vaccine product/platform safety).